| ID Source | ID |
|---|---|
| PubMed CID | 3081210 |
| CHEMBL ID | 420106 |
| SCHEMBL ID | 5606014 |
| MeSH ID | M0167879 |
| Synonym |
|---|
| ac-rgds-nh2 |
| n2-acetyl-l-arginylglycyl-l-alpha-aspartyl-l-serinamide |
| 122207-62-9 |
| acetyl-arginyl-glycyl-aspartyl-serinamide |
| ac-arg-gly-asp-ser-nh2 |
| l-serinamide, n2-acetyl-l-arginylglycyl-l-alpha-aspartyl- |
| CHEMBL420106 , |
| (3s)-3-[[2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(2s)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid |
| 3-[4-amino(imino)methylamino-1-methylcarboxamido-(1s)-butylcarboxamidomethylcarboxamido]-3-[1-carbamoyl-2-hydroxy-(1s)-ethylcarbamoyl]propanoic acid |
| 3-[2-(2-acetylamino-5-guanidino-pentanoylamino)-acetylamino]-n-(1-carbamoyl-2-hydroxy-ethyl)-succinamic acid |
| bdbm50003326 |
| SCHEMBL5606014 |
| DTXSID40153544 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | IC50 (µMol) | 67.2000 | 0.0001 | 0.6323 | 10.0000 | AID60971 |
| Integrin beta-3 | Homo sapiens (human) | Ki | 34.4033 | 0.0010 | 0.9845 | 9.1400 | AID73161; AID73162; AID93298 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 (µMol) | 67.2000 | 0.0001 | 0.7309 | 10.0000 | AID60971 |
| Integrin alpha-IIb | Homo sapiens (human) | Ki | 34.4033 | 0.0020 | 2.3352 | 9.1400 | AID73161; AID73162; AID93298 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID161426 | Inhibition of ADP-induced platelet aggregation in canine platelet-rich plasma | 1992 | Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21 | Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists. |
| AID73161 | Inhibition of [3H]-107260 binding to purified Fibrinogen receptor of human platelets | 1992 | Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21 | Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists. |
| AID73162 | Inhibition of 125[I] Fibrinogen binding to isolated purified human fibrinogen receptor | 1991 | Journal of medicinal chemistry, Oct, Volume: 34, Issue:10 | Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. |
| AID161568 | Inhibition of canine platelet-rich plasma agregation induced by ADP | 1991 | Journal of medicinal chemistry, Oct, Volume: 34, Issue:10 | Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. |
| AID93298 | Inhibition of human washed platelet aggregation | 1991 | Journal of medicinal chemistry, Oct, Volume: 34, Issue:10 | Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. |
| AID60971 | Inhibition of thrombin-stimulated platelet aggregation in dogs | 1991 | Journal of medicinal chemistry, Oct, Volume: 34, Issue:10 | Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||